How Trenbolone Affects ALT (Liver Enzymes)

Trenbolone acetate and trenbolone enanthate are injectable 17-beta esterified steroids, not 17-alpha alkylated. The 17-alpha alkylation modification (present in oral steroids like stanozolol, oxymetholone, and methandrostenolone) is the structural feature most strongly associated with direct hepatocellular toxicity because it allows first-pass hepatic survival at high concentrations.

Because trenbolone lacks this modification, it was long considered hepatically safe. The evidence is more nuanced:

1. Muscle-derived enzyme elevation: AST and ALT are both expressed in skeletal muscle. Heavy resistance training with supraphysiological androgens routinely produces AST/ALT elevations of 2-5x the upper limit of normal (ULN). Dickerman et al. (1999) confirmed that GGT remained normal in all exercising groups regardless of AAS use, while only hepatitis patients showed GGT elevation alongside AST/ALT. Pertusi et al. (2001) found 63% of physicians incorrectly diagnosed liver disease in bodybuilders based on elevated AST/ALT alone.

2. Rare but documented hepatic injury: Boks et al. (2017) published a case report of biopsy-confirmed cholestatic hepatitis from injectable trenbolone enanthate. The mechanism may involve androgen receptor-mediated effects on bile salt export pump (BSEP) and multidrug resistance-associated protein 2 (MRP2), causing cholestasis without the massive transaminase elevations typical of 17-alpha alkylated injury.

3. GGT as the discriminator: Gamma-glutamyl transferase (GGT) is expressed in the liver but not in skeletal muscle. When AST and ALT are elevated but GGT is normal, the source is almost certainly muscle. When GGT rises alongside AST/ALT, hepatic involvement becomes the primary concern.

AST and ALT on trenbolone (most users):

• Elevated 2-5x ULN from resistance training and androgen-enhanced muscle damage
• This is a muscle signal, not a liver signal
• GGT remains normal in this scenario

GGT on trenbolone (rare hepatic involvement):

• GGT above 2x ULN alongside elevated AST/ALT suggests genuine hepatic injury
• GGT above 3x ULN with AST/ALT elevation is a stop signal

If co-administering oral 17-alpha alkylated compounds:

• Expect more pronounced hepatic enzyme elevation
• GGT elevation is more likely
• The oral compound, not trenbolone, is typically the primary hepatotoxic driver

Include GGT on every trenbolone cycle panel. Standard liver function tests (AST, ALT, ALP, bilirubin) are insufficient without GGT because they cannot distinguish muscle from liver origin.

Baseline: Full liver panel including GGT before starting the cycle. Week 6-8: Recheck GGT alongside AST/ALT. If running oral AAS alongside tren: Check liver panel at week 4 as well.

Interpretation guide:

• AST/ALT elevated, GGT normal, CK elevated: muscle origin, monitor
• AST/ALT elevated, GGT above 2x ULN: hepatic involvement, reduce or stop orals
• GGT above 3x ULN with concurrent AST/ALT elevation: stop cycle, clinical evaluation
• Clinical jaundice (yellow skin/eyes): emergency presentation regardless of blood values

• Do not panic over elevated AST/ALT alone on trenbolone. Check GGT first
• If GGT is normal, the elevation is almost certainly from training. Reduce training volume briefly and retest if concerned
• If GGT is elevated, stop all oral AAS immediately. If only running injectable tren, reduce dose or stop
• TUDCA (tauroursodeoxycholic acid) at 500 mg/day may provide hepatoprotection through bile acid modulation, which is relevant to the cholestatic mechanism seen with injectable tren
• NAC (N-acetylcysteine) at 600-1200 mg/day supports glutathione synthesis but addresses a different mechanism (oxidative stress) than cholestasis